Prevention of type 2 diabetes: the long and winding road

The Lancet

Volumn 374, Issue 9702, 2009, Pages 1655-1656

  Misra, Anoop ^a  

^a Fortis Hospitals   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; GLUCAGON LIKE PEPTIDE; METFORMIN; PHENFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE;

ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; DIET THERAPY; ETHNIC DIFFERENCE; EXERCISE; HUMAN; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

DIABETES MELLITUS, TYPE 2; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; LIFE STYLE; PREDIABETIC STATE; RESEARCH DESIGN; RISK REDUCTION BEHAVIOR;

EID: 70449565150     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61631-7     Document Type: Note

References (12)

1. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
2. Crandall J.P., Knowler W.C., Kahn S.E., et al., for the Diabetes Prevention Program Research Group. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab 4 (2008) 382-393
3. Tuomilehto J., Lindstrom J., Eriksson J.G., et al., for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
4. Hamman R.F., Wing R.R., Edelstein S.L., et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 29 (2006) 2102-2107
5. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M., and for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359 (2002) 2072-2107
6. Ramachandran A., Snehalatha C., Mary S., Mukesh B., Bhaskar A.D., Vijay V., and Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49 (2006) 289-297
7. Walker E.A., Molitch M., Kramer M.K., et al. Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 29 (2006) 1997-2002
8. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcome Study. Lancet (2009) 10.1016/S0140-6736(09)61457-4 published online Oct 29.
9. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 26 (2003) 977-980
10. Riccardi G., Rivellese A.A., and Giacco R. Role of glycemic index and glycemic load in the healthy state, in prediabetes, and in diabetes. Am J Clin Nutr 87 (2008) 269S-274S
11. Misra A., Alappan N.K., Vikram N.K., et al. Effect of supervised progressive resistance-exercise training protocol on insulin sensitivity, glycemia, lipids, and body composition in Asian Indians with type 2 diabetes. Diabetes Care 31 (2008) 1282-1287
12. Misra A., and Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 93 suppl 1 (2008) S9-S30